Akari Therapeutics plc ADS (NASDAQ: AKTX)
$1.2500
+0.1000 ( +8.70% ) 12.4K
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Market Data
Open
$1.2500
Previous close
$1.1500
Volume
12.4K
Market cap
$33.09M
Day range
$1.1300 - $1.2600
52 week range
$0.9000 - $4.4000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 425 | Other | 1 | Oct 15, 2024 |
| 424b3 | Other | 37 | Oct 11, 2024 |
| effect | Other | 1 | Oct 11, 2024 |
| corresp | Comment letters | 1 | Oct 09, 2024 |
| s-4/a | Other | 107 | Oct 09, 2024 |
| 8-k | 8K-related | 11 | Oct 04, 2024 |
| 4 | Insider transactions | 1 | Oct 02, 2024 |
| corresp | Comment letters | 2 | Sep 30, 2024 |
| s-4/a | Other | 100 | Sep 30, 2024 |
| upload | Comment letters | 2 | Sep 26, 2024 |